July/August 2014

Ocular Drug Delivery: The Evolution of Retina Practice Continues

Allen C. Ho, MD, and Robert L. Avery, MD

Systemic Pharmacokinetics of Anti-VEGF Compounds Following Ocular Injections

An interview with Robert L. Avery, MD

Medical Update

High-Deductible Health Plans: Implications for the Retina Specialist

Retina specialists need to adjust to the growing number of patients enrolled in high-deductible health plans to ensure that their offices run smoothly.

George A. Williams, MD

The Basics of a Pre-IND Meeting

Meetings with regulatory boards provide guidance to researchers who seek to comply with regulatory requirements and ease the drug approval process.

Aron Shapiro

So You Are Going to Be a Retina Fellow?

Outgoing fellows from Wills Eye Hospital share some tips for maximizing the fellowship experience.

Ehsan Rahimy, MD; with Michael Dollin, MD; John D. Pitcher III, MD; and Christopher Brady, MD

Coding for Retina and Vitreous Procedures Using a Drug Delivery System

Riva Lee Asbell

A No-Touch Technique for Removal of a Dexamethasone Implant

The sustained-delivery device can migrate to the anterior chamber if the posterior capsule is compromised.

John D. Pitcher III, MD

Innovations in 27-Gauge Vitrectomy for Sutureless Microincision Vitrectomy Surgery

Duty cycle control and dual-port cutters may allow wider use of ultrasmall-gauge vitrectomy.

Shunsuke Osawa, MD, and Yusuke Oshima, MD

Case Report: Retinal Detachment in a Patient With Incontinentia Pigmenti

Yew Chong Yap, FRCOphth; Atul Shah, FRCOphth; and Roland Ling, FRCOphth

The Seasick Pattern of Choroidal Lymphoma on Enhanced Depth Imaging Optical Coherence Tomography

Carl G. Schubert, BA; Sruthi Arepalli, MD; and Carol L. Shields, MD

Reducing Damage and Improving Results with Photocoagulation

Use of fluorescein angiogram and indocyanine green imaging combined with subthreshold laser allows greater gains in visual acuity.

Michael D. Bennett, MD

Practical Guidelines for RVO Management

The availability of multiple treatment options is both a blessing and a curse.

Masumi G. Asahi, BS; Marvin Dang, BS; and Ron P. Gallemore, MD, PhD

Ziv-Aflibercept as a Possible Alternative to Aflibercept

Will the story of aflibercept and ziv-aflibercept be a case of déjà vu that recalls the case of ranibizumab and bevacizumab?

Jonathan S. Chang, MD; Thomas A. Albini, MD; and Andrew A. Moshfeghi, MD, MBA

A Peek Down the Pipeline: Emerging Drug Delivery Options for Retinal Disease

Steven Yeh, MD; Thomas A. Albini, MD; and Andrew A. Moshfeghi, MD, MBA

Long-Acting Anti-VEGF Delivery

The potential of a posterior segment delivery system was evaluated in a phase 1 trial.

Roman G. Rubio, MD

Achieving Drug Delivery Via the Suprachoroidal Space

Use of the suprachoroidal space for drug delivery may achieve sustained delivery of therapeutics close to the source of retinal or choroidal pathology.

Debra A. Goldstein, MD

Ocular Drug Delivery Via Micro- and Nanoparticles

A proprietary noninflammatory particle platform may unlock the potential to deliver large- and small-molecule therapeutics.

An interview with Michael O'Rourke and Justin Hanes, PhD

5 Questions with Derek Y. Kunimoto, MD, JD

Derek Y. Kunimoto, MD, JD, is a co-managing partner at Retinal Consultants of Arizona and a director at Scottsdale Eye Surgery Center in Scottsdale, AZ.